CLOs on the Move

Mobile Medical Corporation

www.mobmed.com

 
Mobile Medical Corporation is a Bethel Park, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ALCO Sales and Service Co.

However, ALCO can make the following promises and keep them: ALCO promises to earn your trust by providing superior service and products. Good customers deserve the best and we review your orders to assure you get exactly what you ordered. Quality,

Abbott House

The Abbott Union Free School District provides programs especially designed for children with special needs.

Braswell'S Chateau Villa

Braswell'S Chateau Villa is a Redlands, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centrix Inc.

Centrix, Inc. manufactures and sells a complete line of dental products to the dental industry. We do this through a hybrid marketing channel of both direct and dealer distributor sales.

Allergen Research

Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.